-

Insulet to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 12, 2021 at 9:10 a.m. (Eastern Time)

To listen to the live audio webcast of the presentation, please visit http://investors.insulet.com. A replay of the audio webcast will also be available following the event.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: www.insulet.com and www.myomnipod.com.

Contacts

Investor Relations:

Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717
dgordon@insulet.com

Jason McGorman
Principal Investor Relations Analyst
(978) 600-7627
jmcgorman@insulet.com

Media:

Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com

Industry:

Insulet Corporation

NASDAQ:PODD
Release Versions
English

Contacts

Investor Relations:

Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717
dgordon@insulet.com

Jason McGorman
Principal Investor Relations Analyst
(978) 600-7627
jmcgorman@insulet.com

Media:

Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com

More News From Insulet Corporation

Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 11:15 a.m. (Pacific Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation:...

Insulet Expands Omnipod® U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod brand of products, has announced the expansion of its U.S. Pod recycling program, which is now available to all U.S. customers. “Here at Insulet, our mission is to transform the lives of people with diabetes, and we are equally committed to creating a more sustainable future,” said Carolyn Sleeth, Senior Vice President and U.S. Ge...

Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a new benchmark in tubeless diabetes technology by offering a lower 100 mg/dL Target Glucose option and a more seamless automated experie...
Back to Newsroom